eXoZymes (EXOZ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Sep, 2026Executive summary
Annual meeting scheduled for November 13, 2026, to be held virtually; shareholders will vote on director elections and auditor ratification.
Proxy materials, including the 2025 Annual Report, are distributed via mail and online access; voting can be done by internet, phone, or mail.
Record date for voting is September 15, 2026; quorum requires a majority of outstanding shares.
Voting matters and shareholder proposals
Shareholders will elect six directors for a one-year term and ratify RBSM LLP as the independent auditor for 2026.
Board recommends voting FOR all director nominees and FOR auditor ratification.
Shareholder proposals for the 2027 meeting must be submitted by July 16, 2027, for inclusion in the next proxy statement.
Board of directors and corporate governance
Board consists of six members, with a majority being independent as per Nasdaq rules.
Chairman and CEO roles are separated; Christopher Marlett serves as Chairman.
Board committees include Audit, Compensation, and Nominating, each composed of independent directors.
Directors are encouraged to attend annual meetings; all attended at least 75% of meetings in 2025.
Code of business conduct and insider trading policies are in place.
Directors and officers are covered by indemnification agreements and liability insurance.
Latest events from eXoZymes
- Virtual meeting to elect six directors and ratify auditor RBSM LLP for 2026.EXOZ
Proxy filing - 10x NCT productivity gain, $5.65M cash, but long-term funding uncertainty persists.EXOZ
Q2 2026 - Net loss increased 27.7% year-over-year as cash reserves declined and funding needs intensified.EXOZ
Q1 2026 - AI-driven cell-free platform delivers rare molecules at scale, targeting multi-billion-dollar markets.EXOZ
Investor presentation - Cell-free biomanufacturing platform targets $200B+ markets with rapid, high-purity product launches.EXOZ
Investor presentation - Cell-free biomanufacturing platform targets $200B+ markets with rapid, scalable product launches.EXOZ
Investor presentation - Scalable NCT production unlocks new metabolic health solutions for global wellness and pharma markets.EXOZ
Investor presentation - NCT reached kilo-scale production as operating expenses rose and financing preparations advanced.EXOZ
Q4 2025 - Shelf registration for $50M in securities supports cell-free biotech growth amid high risk.EXOZ
Registration Filing